In the Margins
In its annual report, Sequoia Fund manager Ruane, Cuniff & Goldfarb has vented about Valeant Pharmaceuticals' recent stock plunge, though it offers an optimistic outlook for the stock. The letter outlines how much Valeant’s relationship with affiliated pharmacy Philidor wreaked havoc for the fund company. Read the original story from Barron's.
Most Read
Mutual fund independent directors earned more in 2024 than in the year prior, and the pace at which their compensation grew was also higher year-on-year, according ...
The two longest-serving independent directors of ASA Gold and Precious Metals Ltd. have resigned from the board, and all litigation pursued by activist investor Saba Capital ...
Fund Board Views has refreshed and expanded its Editorial Think Tank ahead of its 10-year anniversary this fall. The nine members will continue to work closely with ...
The Securities and Exchange Commission last week dismissed charges against the defendants in the first-ever case related to enforcement of the liquidity risk management rule adopted ...